Items Tagged ‘T cell therapy’

September 3rd, 2014

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Reported to be Effective in Aggressive Non-Hodgkin’s Lymphoma at the National Cancer Institute (NCI)


SANTA MONICA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin’s lymphoma with an anti-CD19 chimeric […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, anti-CD19, dlbcl, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, News, nhl, Non-Hodgkin's Lymphoma, Recurrent Non-Hodgkin's Lymphoma, T cell therapy